Trial Profile

An Open-Label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-Line Treatment of Subjects With Stage IIIBwet/IV Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pazopanib (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
10 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
18 May 2012 Phase II part of the study will not be progressed as documented in Protocol Amendment 01.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com